Genetic Risk Score May Predict Progression of Early-Stage Breast Cancer
Table of Contents
A new study suggests genetic analysis could help determine whether abnormal breast cells will develop into invasive cancer, potentially reducing unneeded treatments for women diagnosed with early-stage disease.
For women facing a diagnosis of abnormal breast changes, a crucial question looms: will these cells progress to invasive breast cancer? Now, research indicates a genetic risk score – derived from analyzing hundreds of common genetic variants – may offer a more personalized prediction than current methods. DCIS (ductal carcinoma in situ) and LCIS (lobular carcinoma in situ) represent abnormal cells confined to the breast ducts or lobules,respectively.While not immediately life-threatening, they can sometimes evolve into invasive cancer.
Researchers analyzed data from nearly 3,000 women – approximately 90% with DCIS and the remainder with LCIS – utilized DNA analysis to scrutinize the cancers for 313 common genetic variants. Researchers combined these results into a single genetic risk score.
the findings revealed a clear correlation: women with higher scores were significantly more likely to develop invasive breast cancer later on. Importantly, this genetic prediction held true regardless of other factors like age or the type of treatment received.
“Until now, treatment decisions have mostly been based on how these cells look under a microscope,” explained a clinical information analyst at King’s College in London. “But these findings suggest that predicting which women are more likely to develop invasive breast cancer shouldn’t just rely on those methods.” She emphasized the need to consider a woman’s genetic risk, family history, and lifestyle factors for a more complete assessment. “By looking at the full picture, we can give women more accurate information about their personal risk of recurrence and help them make more informed choices.”
Toward Personalized Breast Cancer Care
Experts believe this research could be a notable step toward more tailored treatment plans. “Currently, we do not have a reliable system to predict which women with DCIS or LCIS will go on to develop invasive cancer,” stated a breast medical oncologist with the ohio State University Comprehensive Cancer Center in Columbus. The risk score, she added, could identify those at higher risk of developing cancer in either the same or opposite breast.
In practice, this could mean more intensive surveillance and risk-reduction strategies – including medications like tamoxifen or aromatase inhibitors – for high-risk women.conversely, those found to be at lower risk might be able to avoid unnecessary treatments and their associated side effects, optimizing healthcare resources.
Limitations and Future Directions
While promising, the study’s findings are not yet ready to dictate treatment decisions. A medical oncologist at Stanford Medicine in California cautioned that the study was retrospective, meaning it analyzed existing patient records rather than following individuals over time. This limits the ability to definitively prove that using the genetic test would improve cancer outcomes.
Further validation is needed, notably with a larger sample size and a more diverse population. the current study population was overwhelmingly comprised of women of British and European descent, raising questions about its applicability to other ethnicities. A future study should include a more diverse population to ensure the findings are broadly applicable.
Genetic Testing: A Personalized approach?
Should women with stage 0 breast cancer proactively seek genetic testing? Experts suggest it may provide valuable information, but the decision should be made in consultation with a healthcare team.
Genetic testing can identify inherited gene changes – such as BRCA1 and BRCA2 – that increase breast cancer risk. This information can inform screening decisions, preventive measures, and treatment options. Though, testing isn’t necessary for all women with DCIS or LCIS, and is moast beneficial for those with a strong family history of breast or ovarian cancer, a younger age at diagnosis, or other risk factors. A genetic counselor can definitely help individuals navigate these considerations and interpret the results.
Ultimately, this research offers a glimpse into a future where breast cancer treatment is more precise and personalized, minimizing unnecessary interventions and maximizing positive outcomes for women facing an early-stage diagnosis.
